SCHEMBL2951402

SCHEMBL2951402

COc1ccc(C2=CC3=CC4=NC(=CC5=NC(=CC6=NC(=CC2=N3)C=C6)C=C5)C=C4)cc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 2/20 0.36
▸ KDM4E B2RXH2 9/20 0.35
▸ ALDH1A1 P00352 8/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ HPGD P15428 4/20 0.35
▸ MAPK1 P28482 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ MPI P34949 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PDGFRB P09619 1/20 0.34
▸ PDGFRA P16234 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9429848 0.90 MAPT (0.36) KDM4EALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL5576185 0.88 POLB (0.40) KDM4EALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2950392 0.85 KDM4E (0.36) KDM4EALDH1A1MAPTHPGDMAPK1
SCHEMBL29148790 0.84 AMY1A (0.34) —
SCHEMBL28098902 0.81 MAPT (0.40) KDM4EMAPTMAPK1MEN1KMT2A
SCHEMBL27910483 0.81 MAPT (0.40) KDM4EMAPTMAPK1MEN1KMT2A
SCHEMBL27765965 0.80 KDM4E (0.45) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL2942317 0.79 CYP1A1 (0.34) KDM4EALDH1A1
SCHEMBL5319098 0.77 — —
SCHEMBL1945083 0.77 ALDH1A1 (0.36) KDM4EALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110394189-A A kind of catalyst and preparation method thereof for high efficiency photocatalysis degradation 1,5- dihydroxy naphthlene UNIV BEIJING CHEM TECH 2019-11-01 — — CN claimed
WO-2017051435-A1 CHLORIN BASED COMPOUNDS, A PROCESS FOR PREPARATION THEREOF AND USE AS PHOTODYNAMIC THERAPEUTIC AGENTS AND FLUORESCENT PROBES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-03-30 — — WO claimed
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 — — EP disclosed
CN-110394189-A A kind of catalyst and preparation method thereof for high efficiency photocatalysis degradation 1,5- dihydroxy naphthlene UNIV BEIJING CHEM TECH 2019-11-01 — — CN disclosed
WO-2017051435-A1 CHLORIN BASED COMPOUNDS, A PROCESS FOR PREPARATION THEREOF AND USE AS PHOTODYNAMIC THERAPEUTIC AGENTS AND FLUORESCENT PROBES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-03-30 — — WO disclosed
US-20160205925-A1 ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2016-07-21 — — US disclosed
EP-1357912-B9 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-06-13 — — EP disclosed
US-7850981-B2 Immuno-adjuvant PDT treatment of metastatic tumors QLT, INC. (CA) 2010-12-14 — — US disclosed
US-7753943-B2 Reduced fluence rate PDT QLT INC. (CA) 2010-07-13 — — US disclosed
WO-2010069073-A1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE QLT INC. (CA) 2010-06-24 — — WO disclosed
US-20100040546-A1 Biological targeting compositions and methods of using the same SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2010-02-18 — — US disclosed
US-20030099596-A1 Treatment of macular edema BAUSCH HEALTH IRELAND LIMITED (IE) 2003-05-29 — — US disclosed
US-20030087889-A1 Photodynamic therapy of occult age-related macular degeneration BAUSCH HEALTH COMPANIES INC. (CA) 2003-05-08 — — US disclosed
US-20030083649-A1 Method for reducing or preventing PDT related inflammation VALEANT SP. Z.O.O. (PL) 2003-05-01 — — US disclosed
US-20020183302-A1 Method to prevent vision loss TECHNOLAS PERFECT VISION GMBH (DE) 2002-12-05 — — US disclosed
US-20020173832-A1 Reduced fluence rate PDT TECHNOLAS PERFECT VISION GMBH (DE) 2002-11-21 — — US disclosed
US-20020156062-A1 Drug delivery system for hydrophobic drugs BAUSCH HEALTH COMPANIES INC. (CA) 2002-10-24 — — US disclosed
US-20020155089-A1 Drug delivery systems for photodynamic therapy UNIVERSITY OF BRITISH COLUMBIA, THE (CA) 2002-10-24 — — US disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 — — US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030099596-A1 Treatment of macular edema VEGFA, PPOX, FLT4 PDE4A 167/4885KDM4E 2230/4885ALDH1A1 3216/4885
US-20020183302-A1 Method to prevent vision loss VEGFA, ALDH1A2, PDE6C PDE4A 652/4885KDM4E 3259/4885ALDH1A1 901/4885
US-20020156062-A1 Drug delivery system for hydrophobic drugs LIPA, MLEC, ABCG2 PDE4A 3677/4885KDM4E 3305/4885ALDH1A1 2604/4885
US-20020155089-A1 Drug delivery systems for photodynamic therapy PIN1, PPOX, DHFR PDE4A 1860/4885KDM4E 1989/4885ALDH1A1 701/4885
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA PDE4A 2628/4885KDM4E 3097/4885ALDH1A1 371/4885
US-20160205925-A1 ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER CUTA, POLR1C, PUF60 PDE4A 4423/4885KDM4E 3572/4885ALDH1A1 1405/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 PDE4A 4645/4885KDM4E 4361/4885ALDH1A1 794/4885
US-20030087889-A1 Photodynamic therapy of occult age-related macular degeneration ALDH1A2, AGER, CRY2 PDE4A 1074/4885KDM4E 3312/4885ALDH1A1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback